•Genomic characterization determines diagnosis, classification, and prognostication of the myeloid malignancies myelodysplastic syndrome (MDS) and AML. •Recognizing genetic lesions as invariable ...
NPM1-mutated AML prognosis was refined using a new genetic model integrating co-mutations, improving risk classification and ...
Errata: Environmental Impact Assessment of Intravenous Versus Subcutaneous Monoclonal Antibodies: A Carbon Footprint Analysis The classification of AML and therapeutic options are now largely driven ...
SAN JOSE, Calif., Jan. 11, 2024 /PRNewswire/ -- AI HealthTech startup AHEAD Medicine Corporation is delighted to announce its poster presentation at the esteemed American Society of Hematology (ASH) ...
Companion diagnostic would be used following potential regulatory approval of entospletinib to screen for NPM1 mutation present in approximately one-third of all patients with AML Entospletinib is ...
The occurrence of treatment-related myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) after autologous hematopoietic cell transplantation (HCT) for multiple myeloma was associated with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback